sever
fever
thrombocytopenia
syndrom
sft
emerg
infecti
diseas
local
china
japan
korea
character
sever
hemorrhag
high
fatal
rate
current
specif
vaccin
treatment
approv
diseas
develop
therapeut
agent
sft
isol
antibodi
phagedisplay
antibodi
librari
construct
patient
recov
sft
viru
sftsv
infect
one
antibodi
design
reactiv
gn
envelop
glycoprotein
sftsv
protect
host
cell
mice
infect
vitro
vivo
experi
notabl
protect
mice
even
inject
day
inocul
lethal
dose
sftsv
use
crosslink
assist
mass
spectrometri
alanin
scan
locat
nonlinear
epitop
gn
glycoprotein
domain
ii
unstructur
stem
region
suggest
may
inhibit
conform
alter
critic
cell
membran
fusion
viru
host
cell
react
recombin
gn
glycoprotein
strain
addit
base
epitop
predict
bind
gn
glycoprotein
sftsv
isol
previous
report
togeth
data
suggest
potenti
develop
therapeut
agent
could
protect
report
sftsv
isol
sinc
isol
novel
viru
case
acut
infecti
diseas
call
sever
fever
thrombocytopenia
syndrom
sft
risen
rapidli
china
japan
korea
pose
risk
public
health
increas
fear
tick
transmit
deadli
sft
viru
sftsv
emerg
tickborn
viru
infect
peopl
china
averag
case
fatal
rate
initi
report
sporad
sft
case
south
korea
japan
south
korea
report
case
averag
case
fatal
japan
report
case
averag
fatal
tick
haemaphysali
longicorni
rhipicephalu
microplu
implic
promin
vector
transmit
sftsv
regard
sftsv
host
variou
vertebr
speci
consid
infect
evidenc
high
sftsv
seropreval
domest
anim
sft
endem
region
addit
report
case
humantohuman
transmiss
contact
blood
bodi
fluid
includ
infect
healthcar
worker
patient
pose
threat
public
furthermor
discoveri
h
longicorni
tick
unit
state
indic
possibl
sftsv
could
spread
contin
highlight
need
prevent
diseas
transmiss
sftsv
singlestrand
negativesens
tripartit
rna
viru
classifi
member
phleboviru
genu
phenuivirida
famili
bunyavirial
order
genom
sftsv
compris
l
segment
encod
rnadepend
rna
polymeras
l
segment
envelop
gn
glycoprotein
segment
envelop
gc
glycoprotein
segment
nucleoprotein
segment
nonstructur
protein
segment
phylogenet
analysi
base
genom
sequenc
sftsv
isol
found
substanti
genet
divers
accumul
mutat
suggest
sftsv
exist
decad
minimum
howev
differ
virul
sftsv
sublineag
yet
determin
major
clinic
featur
sft
includ
high
fever
bodi
temperatur
fatigu
malais
anorexia
nausea
vomit
diarrhea
thrombocytopenia
leukocytopenia
abdomin
pain
sever
case
sft
includ
central
nervou
system
manifest
hemorrhag
sign
multipl
organ
dysfunct
lead
death
vaccin
therapeut
specif
sft
approv
human
use
recent
phase
clinic
trial
favipiravir
avigan
drug
approv
treatment
influenza
viru
infect
japan
initi
expand
indic
sft
treatment
monoclon
antibodi
convalesc
sera
sft
patient
test
identifi
potenti
therapeut
intervent
target
result
identif
sftsv
glycoprotein
molecul
requir
host
cell
entri
also
critic
target
viru
neutral
develop
humor
immun
gn
gc
envelop
glycoprotein
sftsv
type
transmembran
protein
gc
propos
membran
fusion
protein
critic
sftsv
infect
also
shown
rift
valley
fever
viru
rvfv
wellknown
phleboviru
wherea
function
gn
remain
larg
elus
across
speci
genu
phleboviru
structur
gn
head
domain
compos
three
subdomain
resolv
sftsv
rvfv
howev
homolog
arrang
within
subdomain
differ
consider
two
virus
structur
gn
stem
domain
still
remain
unknown
moreov
gener
antibodi
target
infect
human
rare
due
presenc
immunodomin
decoy
epitop
nucleoprotein
common
phenomenon
pathogen
virusinfect
host
anim
model
howev
protect
effect
human
convalesc
sera
shown
suggest
antibodi
therapi
possibl
thu
far
human
neutral
monoclon
antibodi
report
develop
use
combinatori
human
antibodi
librari
five
patient
bind
domain
iii
sftsv
gn
glycoprotein
neutral
effect
shown
vitro
vivo
efficaci
remain
shown
studi
construct
antibodi
librari
patient
recov
sft
select
antibodi
gn
gc
glycoprotein
among
antibodi
bound
gn
glycoprotein
show
potent
neutral
effect
vitro
protect
effect
vivo
addit
character
conform
epitop
use
crosslink
coupl
mass
spectrometri
test
reactiv
alanin
mutant
allow
us
estim
strain
coverag
human
embryon
kidney
hek
cell
produc
gn
gc
glycoprotein
fuse
crystalliz
fragment
human
immunoglobulin
ig
heavi
chain
constant
region
gnfc
gcfc
fuse
human
ig
kappa
light
chain
constant
region
purifi
protein
affin
chromatographi
construct
phagedisplay
singlechain
variabl
fragment
scfv
antibodi
librari
complex
coloni
form
unit
use
peripher
blood
mononuclear
cell
isol
patient
recov
sft
phagedisplay
antibodi
librari
coverag
level
subject
four
round
biopan
either
recombin
gnfc
gcfc
fusion
protein
conjug
paramagnet
bead
randomli
select
phagemid
clone
output
titer
plate
last
round
biopan
subject
clone
phage
enzymelink
immunosorb
assay
elisa
minim
number
clone
reactiv
fc
portion
fusion
protein
use
antigen
posit
clone
select
subject
sanger
sequenc
determin
scfv
nucleotid
sequenc
identifi
five
clone
reactiv
gn
five
clone
reactiv
gc
scfv
clone
express
scfv
antibodi
fuse
fc
scfvfc
cell
purifi
affin
test
antibodi
abil
reduc
cytopath
effect
cpe
caus
sftsv
fig
one
antign
antibodi
design
extrem
effect
neutral
sftsv
shown
reduct
percentag
cell
show
cpe
focu
reduct
neutral
test
frnt
also
show
significantli
higher
potenc
compar
candid
antibodi
fig
v
h
sequenc
share
ident
germlin
exclud
heavi
chain
complementari
determin
region
hcdr
wherea
v
sequenc
share
ident
germlin
fig
immunofluoresc
assay
ifa
use
vero
cell
antign
antibodi
determin
proport
gn
glycoprotein
produc
cell
infect
sftsv
measur
neutral
potenc
mean
sd
vero
cell
produc
gn
glycoprotein
administ
concentr
nm
fig
antibodi
appli
concentr
cell
produc
gn
glycoprotein
cell
protect
antibodi
cell
produc
gn
glycoprotein
cell
incub
sftsv
produc
gn
glycoprotein
measur
neutral
efficaci
scfvfc
fusion
protein
mix
tcid
sftsv
strain
ad
vero
cell
incub
h
cell
wash
cultur
day
gn
glycoprotein
produc
infect
vero
cell
detect
immunofluoresc
assay
use
antisftsv
gn
glycoprotein
antibodi
compet
bind
least
five
technic
replic
fluoresc
signal
intens
stain
sftsv
gn
glycoprotein
use
quantit
indic
viral
infect
proport
infect
cell
compar
nontreat
cell
defin
rel
cell
infect
plot
scfvfc
fusion
protein
also
treat
parallel
experi
error
bar
repres
standard
deviat
sd
asterisk
indic
statist
signific
differ
determin
nonparametr
friedman
test
post
hoc
dunn
multipl
comparison
test
p
p
p
p
b
repres
imag
treatment
group
shown
scale
bar
sftsv
gn
glycoprotein
nuclei
stain
fitc
green
dapi
blue
respect
anim
studi
lethal
dose
strain
sftsv
determin
type
interferon
interferon
receptor
gene
defici
mice
n
per
group
mice
subcutan
inject
dose
either
use
antibodi
protect
model
mice
n
per
group
subcutan
inject
strain
sftsv
dose
either
pfu
h
mice
intraperiton
administ
either
phosphatebuff
salin
pb
human
igg
isotop
control
antibodi
dose
approxim
correspond
mgkg
bodi
weight
day
h
interv
inject
amount
antibodi
perform
fig
group
treat
pb
isotyp
control
antibodi
mice
die
within
day
viral
dose
fig
dpi
dose
pfu
approxim
bodi
weight
lost
dpi
pfu
bodi
weight
lost
mice
treat
surviv
viral
dose
weight
loss
treatment
death
occur
mice
treat
pfu
viral
dose
mice
treat
pfu
dose
signific
weight
loss
also
observ
mice
delay
treatment
model
antibodi
treatment
start
dpi
continu
consecut
day
fig
pfu
viral
dose
mice
surviv
treatment
delay
dpi
surviv
treatment
delay
dpi
fig
mice
treat
dpi
signific
weight
loss
pfu
viral
dose
delay
antibodi
treatment
dpi
protect
mice
respect
mice
treatment
delay
dpi
lose
weight
wherea
mice
treatment
delay
dpi
lost
bodi
weight
treatment
delay
dpi
later
mice
die
check
reactiv
sftsv
strain
overexpress
purifi
recombin
gn
glycoprotein
sftsv
strain
bind
intact
viru
particl
also
confirm
use
elisa
virusco
microtit
plate
fig
among
sftsv
strain
sequenc
deposit
viru
pathogen
databas
analysi
resourc
vipr
select
strain
belong
differ
cluster
fig
compar
reactiv
wellknown
viru
isol
china
japan
success
overexpress
gn
glycoprotein
fc
fusion
protein
subject
protein
elisa
igg
success
bound
gn
glycoprotein
strain
dosedepend
manner
concentr
rang
pm
nm
fig
addit
amount
antibodi
bound
gn
glycoprotein
coat
elisa
plate
higher
glycoprotein
test
concentr
also
found
reactiv
gn
glycoprotein
strain
fig
use
surfac
plasmon
reson
analys
determin
kinet
bind
gn
glycoprotein
bound
gn
glycoprotein
equilibrium
dissoci
constant
k
pm
associ
rate
k
dissoci
rate
k
fig
immunoblot
analysi
use
recombin
gn
glycoprotein
gangwonkorea
strain
react
gn
glycoprotein
wherea
antign
antibodi
discov
site
bind
perform
crosslink
coupl
mass
spectrometri
use
deuterium
isotopelabel
homobifunct
linker
form
coval
bond
amino
acid
residu
within
interfac
antibodyantigen
complex
describ
previous
found
crosslink
bound
five
amino
acid
residu
within
domain
ii
sftsv
gn
glycoprotein
also
four
amino
acid
residu
within
stem
region
fig
base
observ
prepar
sever
alaninereplac
mutant
span
test
reactiv
use
elisa
mutant
antign
glycoprotein
antibodi
convalesc
patient
inhibit
infect
sftsv
express
ha
peptid
carboxi
terminu
tag
use
measur
rel
amount
mutant
alanin
mutant
protein
captur
antibodi
coat
elisa
plate
measur
amount
captur
mutant
protein
detect
fc
portion
protein
signal
detect
captur
ha
peptid
use
normal
express
mutant
protein
measur
reactiv
alanin
mutant
gn
protein
rel
wild
type
gn
glycoprotein
found
alanin
replac
amino
acid
residu
domain
ii
result
reduc
rel
reactiv
except
find
consist
result
deduc
crosslink
coupl
mass
spectrometri
fig
stem
region
replac
cystin
residu
reduc
rel
reactiv
observ
consist
previou
report
structur
stabil
gn
disrupt
mutat
also
mutat
flank
residu
cystin
correspond
also
reduc
reactiv
mutat
residu
distant
cystein
residu
mutat
residu
reduc
rel
reactiv
mutat
minor
effect
reactiv
overal
bind
gn
predict
affect
amino
acid
residu
within
domain
ii
stem
region
sftsv
gn
glycoprotein
given
gn
glycoprotein
isol
conserv
sequenc
amino
acid
residu
expect
react
sftsv
isol
current
report
fig
antibodi
play
pivot
role
prevent
viral
entri
cell
induc
lysi
infect
cell
antibodydepend
cellular
cytotox
complementdepend
cytotox
polysera
recov
patient
vaccin
donor
use
prophylact
agent
variou
viral
diseas
includ
hepat
b
rabi
altern
approach
virusdirect
monoclon
antibodi
also
develop
test
therapi
prophylaxi
viral
diseas
palivizumab
synagi
marketapprov
prophylaxi
rsv
addit
antibodi
hiv
rsv
ebola
viru
influenza
viru
demonstr
potent
efficaci
anim
model
antibodi
target
emerg
reemerg
virus
includ
merscov
zika
viru
also
develop
test
clinic
trial
past
sever
decad
antibodi
becom
one
major
therapeut
agent
cancer
autoimmun
diseas
indic
rapidli
broaden
recent
year
recent
technic
improv
discoveri
manufactur
step
therapeut
antibodi
product
also
allow
rapid
success
antibodi
develop
combat
emerg
infecti
diseas
sft
patient
report
china
south
korea
japan
number
patient
increas
year
howev
sft
fatal
vari
among
three
countri
averag
case
fatal
rate
china
south
korea
japan
much
higher
respect
viru
pathogen
databas
analysi
resourc
vipr
sequenc
sftsv
isol
current
deposit
howev
unknown
signific
variabl
virul
isol
previou
report
show
mice
die
day
infect
focu
form
unit
ffu
strain
tcid
strain
base
observ
first
inocul
mice
pfu
strain
observ
mice
die
day
infect
pfu
dose
strain
mice
die
day
infect
increas
virul
also
report
studi
show
similar
fatal
rate
knockout
syrian
hamster
challeng
pfu
strain
also
observ
discrep
bodi
weight
death
studi
anoth
group
data
mice
die
lose
bodi
weight
studi
use
strain
mice
die
lose
bodi
weight
result
might
due
differ
virul
strain
differ
virul
strain
rvfv
phleboviru
similar
sftsv
report
mechan
antibodi
inhibit
viral
replic
insid
host
cell
studi
extens
especi
case
influenza
viru
mostwid
known
mechan
bind
antibodi
portion
viru
interact
host
cell
receptor
therebi
block
interact
viru
host
cell
anoth
group
antibodi
report
bind
stem
region
influenza
hemagglutinin
critic
conform
rearrang
occur
membran
fusion
mechan
potenti
util
clinic
develop
stem
region
fewer
mutat
receptor
bind
site
addit
sever
group
includ
elucid
unconvent
viru
neutral
mechan
affect
infect
step
occur
membran
fusion
crosslink
coupl
mass
spectrometri
alanin
mutant
studi
epitop
confin
domain
ii
stem
region
gn
glycoprotein
although
crystal
structur
phleboviru
gn
glycoprotein
stem
region
yet
solv
recent
report
show
cryoelectron
microscopi
map
rvfv
depict
crystal
structur
rvfv
gn
glycoprotein
head
region
without
stem
region
report
also
describ
membran
fusion
mechan
rvfv
mediat
low
ph
induc
exposur
hydrophob
gc
fusion
loop
neutral
ph
gn
domain
ii
domain
shield
gc
fusion
loop
prefus
state
prevent
prematur
fusion
base
report
hypothes
simultan
bind
domain
ii
stem
region
gn
glycoprotein
prevent
unshield
gc
fusion
loop
conclus
monoclon
antibodi
shown
therapeut
efficaci
mous
sftsv
infect
model
although
neutral
efficaci
test
strain
cultur
vero
cell
confirm
bind
capabl
recombin
sftsv
gn
strain
china
accord
epitop
reveal
studi
estim
interact
major
sftsv
isol
current
report
base
result
believ
suffici
potenti
develop
prophylact
therapeut
agent
broad
varieti
sft
isol
studi
involv
recov
patient
blood
sampl
review
approv
institut
ethic
review
board
seoul
nation
univers
hospit
irb
approv
number
patient
adult
submit
written
inform
consent
anim
studi
conduct
anim
biosafeti
level
facil
institut
pasteur
korea
accord
principl
establish
anim
protect
act
laboratori
anim
act
republ
korea
interferon
receptor
knockout
mice
b
k
univers
hull
uk
bred
rais
genotyp
institut
pasteur
korea
experiment
procedur
review
approv
institut
anim
care
use
committe
institut
pasteur
korea
anim
protocol
number
sftsv
gn
glycoprotein
amino
acid
sequenc
variou
isol
use
studi
retriev
viru
pathogen
databas
analysi
resourc
vipr
obtain
sftsv
gn
glycoprotein
ectodomain
code
dna
strand
human
codon
optim
dna
sequenc
correspond
amino
acid
sequenc
genbank
access
strain
strain
strain
ah
strain
strain
synthes
genscript
piscataway
nj
usa
integr
dna
technolog
coralvil
ia
usa
human
codon
optim
dna
sequenc
sftsv
gc
ectodomain
strain
correspond
sequenc
also
synthes
overexpress
purif
recombin
sftsv
gngc
glycoprotein
ecotodomain
fuse
fc
region
human
immunoglobulin
heavi
constant
term
gnfcgcfc
fuse
human
immunoglobulin
kappa
constant
region
igkc
term
sftsv
gngc
glycoprotein
ectodomain
encod
gene
clone
modifi
vector
invitrogen
carlsbad
ca
usa
leader
sequenc
human
immunoglobulin
kappa
chain
two
sfil
restrict
enzym
site
fc
region
human
human
immunoglobulin
kappa
constant
region
previous
describ
subsequ
vector
use
transfect
hek
invitrogen
cell
invitrogen
use
polyethylenimin
polysci
warrington
pa
usa
transfect
cell
cultur
freestyl
express
medium
gibco
thermo
fisher
scientif
waltham
usa
overexpress
recombin
sftsv
gn
gc
glycoprotein
fusion
protein
purifi
affin
chromatographi
use
mabselect
kappaselect
column
kta
pure
chromatographi
system
ge
healthcar
chicago
il
usa
follow
protocol
provid
manufactur
alaninescan
mutagenesi
sftsv
gn
glycoprotein
amino
acid
residu
substitut
alanin
produc
clone
synthes
dna
fragment
integr
dna
technolog
modifi
vector
describ
subsequ
influenza
hemagglutinin
ha
tag
sequenc
ypydvpdya
introduc
cterminu
fc
region
human
immunoglobulin
heavi
whole
protein
design
gnfcha
produc
describ
order
produc
histidin
tag
sftsv
gn
glycoprotein
ligand
surfac
plasmon
reson
analysi
six
carboxytermin
polyhistidin
residu
design
produc
describ
peripher
blood
mononuclear
cell
patient
recov
sft
collect
use
ficollpaqu
densiti
gradient
medium
ge
healthcar
total
rna
isol
use
trizol
reagent
invitrogen
cdna
synthes
use
superscript
iii
firststrand
cdna
synthesi
kit
oligo
dt
prime
invitrogen
cdna
phagedisplay
librari
human
singlechain
variabl
fragment
scfv
construct
four
round
biopan
perform
select
scfv
antibodi
clone
librari
previous
describ
round
biopan
recombin
sftsv
gnfc
coat
onto
paramagnet
dynabead
invitrogen
use
select
sftsv
glycoprotein
bind
clone
phage
elisa
perform
previous
describ
use
gn
gc
glycoproteinco
microtit
plate
scfv
display
phage
horseradish
peroxidas
hrp
conjug
antibodi
sino
biolog
beij
china
nucleotid
sequenc
posit
scfv
clone
determin
sanger
nucleotid
sequenc
cosmogenetech
seoul
south
korea
germlin
sequenc
select
antibodi
variabl
region
analyz
nation
center
biotechnolog
inform
ncbi
igblast
gene
encod
variabl
heavi
chain
variabl
light
chain
synthes
integr
dna
technolog
genscript
fuse
human
heavi
chain
constant
region
gene
igg
human
kappa
light
chain
gene
clone
eukaryot
express
vector
describ
previous
express
vector
transfect
hek
cell
igg
molecul
purifi
cultur
supernat
affin
chromatographi
use
mabselect
describ
gene
encod
scfvfc
fusion
protein
fusion
protein
synthes
clone
vector
invitrogen
transfect
hek
cell
recombin
protein
overexpress
purifi
describ
sftsv
strain
propag
vero
cell
korean
cell
link
bank
roswel
park
memori
institut
rpmi
medium
lm
welgen
daegu
south
korea
supplement
heatinactiv
fetal
bovin
serum
gibco
penicillinstreptomycin
gibco
fiftyperc
tissu
cultur
infect
dose
tcid
valu
titrat
vero
cell
use
reedmuench
method
scfvfc
fusion
protein
serial
dilut
increment
concentr
mix
equal
volum
tcid
sftsv
incub
h
virusantibodi
mixtur
transfer
onto
vero
cell
chamber
slide
thermo
scientif
waltham
usa
incub
h
noinfectioncontrol
group
viru
ad
cell
contrast
infectioncontrol
group
antibodi
incub
viru
remov
virusantibodi
mixtur
cell
cultur
day
ifa
cultur
cell
fix
paraformaldehyd
pb
h
room
temperatur
slide
block
permeabil
pb
contain
triton
bovin
serum
albumin
follow
incub
antisftsv
gn
glycoprotein
antibodi
overnight
wash
cell
incub
h
room
temperatur
dilut
fluorescein
isothiocyan
fitc
conjug
antirabbit
igg
fc
antibodi
jackson
immunoresearch
west
grove
pa
usa
stain
nucleu
dihydrochlorid
dapi
use
fluoresc
imag
cell
monitor
confoc
laser
scan
microscop
tc
leica
wetzlar
germani
anim
experi
titer
sftsv
measur
plaqu
form
assay
tenfold
serial
dilut
sftsv
inocul
onto
monolay
vero
cell
tissu
cultur
plate
h
room
temperatur
remov
viru
cell
wash
three
time
pb
incub
dulbecco
modifi
eagl
medium
gibco
base
overlay
medium
contain
agar
bd
bioscienc
san
jose
ca
usa
day
visual
plaqu
overlay
medium
remov
cell
fix
paraformaldehyd
pb
follow
stain
wv
crystal
violet
solut
sigmaaldrich
st
loui
mo
usa
either
plaqu
form
unit
pfu
strain
sftsv
pb
inocul
male
femal
mice
subcutan
sc
inject
rout
h
infect
mice
administ
igg
antibodi
pb
vehicl
control
intraperiton
ip
inject
rout
mgkg
bodi
weight
everi
h
consecut
day
palivizumab
medimmun
gaithersburg
md
usa
igg
use
isotyp
control
posit
control
antibodi
respect
delay
treatment
model
infect
mice
treat
antibodi
day
postinfect
dpi
day
consecut
bodi
weight
surviv
mice
monitor
day
postinfect
order
measur
bind
activ
igg
antibodi
halfarea
micropl
corn
corn
ny
usa
coat
gnfc
fusion
protein
incub
overnight
plate
block
skim
milk
pb
h
room
temperatur
plate
wash
pb
receiv
antibodi
serial
dilut
block
buffer
plate
incub
h
room
temperatur
wash
three
time
pb
solut
hrpconjug
antihuman
ig
kappa
light
chain
antibodi
chemicon
temecula
ca
usa
dilut
block
buffer
ad
well
plate
incub
h
room
temperatur
wash
well
receiv
tetramethylbenzidin
tmb
substrat
solut
thermo
scientif
color
reaction
stop
ad
sulfur
acid
absorb
well
measur
nm
use
micropl
spectrophotomet
multiskan
go
thermo
scientif
kinet
gn
glycoprotein
bind
measur
surfac
plasmon
reson
analysi
use
biacor
instrument
sensor
chip
amin
coupl
kit
captur
kit
ge
healthcar
follow
recommend
manufactur
protocol
procedur
condit
reaction
buffer
flow
time
flow
rate
concentr
analyt
briefli
antihistidin
antibodi
immobil
activ
chip
follow
deactiv
step
histidin
tag
inject
flow
cell
prior
antibodi
inject
associ
step
igg
antibodi
pb
concentr
twofold
increment
rang
nm
nm
inject
min
dissoci
step
pb
contain
inject
min
dissoci
step
chip
regener
perform
epitop
antibodi
first
determin
analyz
complex
antibodi
sftsv
antigen
link
deuter
crosslink
covalx
switzerland
previous
describ
briefli
antibodi
antigen
antibodyantigen
complex
character
high
mass
matrixassist
laser
desorptionion
maldi
mass
spectrometri
use
maldi
toftof
tandem
mass
spectromet
autoflex
iii
bruker
billerica
usa
equip
interact
modul
covalx
switzerland
afterward
antibodyantigen
complex
crosslink
dss
isotopelabel
homobifunct
nhydroxysuccinimid
ester
follow
reduct
alkyl
use
dithiothreitol
iodoacetamid
urea
digest
reduc
complex
proteolyt
buffer
compos
trypsin
chymotrypsin
endoproteinas
aspn
elastas
thermolysin
use
sampl
analyz
nanoliquid
chromatographi
ultim
dionex
sunnyval
ca
usa
orbitrap
mass
spectrometri
q
exact
hybrid
quadrupoleorbitrap
thermo
scientif
measur
bind
activ
mutat
gn
antibodi
antiinfluenza
viru
hemagglutinin
antibodi
clone
bio
x
cell
lebanon
nh
usa
coat
micropl
parallel
plate
block
skim
milk
pb
h
room
temperatur
transient
transfect
cell
supernat
contain
recombin
gnfcha
protein
alanin
substitut
ad
well
incub
h
room
temperatur
micropl
wash
three
time
pb
solut
hrpconjug
antihuman
igg
fc
antibodi
invitrogen
dilut
block
buffer
ad
well
plate
incub
h
room
temperatur
wash
well
receiv
tetramethylbenzidin
tmb
substrat
solut
thermo
scientif
color
reaction
stop
ad
sulfur
acid
absorb
well
measur
nm
use
micropl
spectrophotomet
multiskan
go
thermo
scientif
rel
reactiv
calcul
use
absorb
valu
ab
follow
rel
reactiv
ab
mutant
captur
ab
mutant
captur
ha
antibodi
ab
wildtyp
captur
ab
wildtyp
captur
ha
antibodi
elisa
ifa
data
includ
statist
comparison
analyz
graph
use
graphpad
prism
softwar
san
diego
ca
usa
fluoresc
signal
measur
confoc
microscopi
quantifi
use
leica
applic
suit
advanc
fluoresc
softwar
mass
spectrometri
data
analyz
use
xquest
stavrox
softwar
plasmon
surfac
reson
data
analyz
use
biaevalu
softwar
visual
align
phylogen
analys
amino
acid
sequenc
perform
geneiou
softwar
thirti
fifti
focu
form
unit
ffu
sftsv
incub
serial
dilut
scfvfc
fusion
protein
h
room
temperatur
transfer
vero
cell
tissu
cultur
plate
incub
h
co
incub
cell
overlaid
methylcellulos
rpmi
medium
fetal
bovin
serum
cultur
day
cell
fix
icecold
methanol
min
incub
bovin
serum
albumin
pb
h
sftsv
local
cluster
foci
visual
incub
antisftsv
gc
glycoprotein
antibodi
clone
patent
h
follow
incub
dilut
goat
antirabbit
igg
fc
fragment
specif
antibodi
conjug
hrp
jackson
immunoresearch
west
grove
pa
usa
min
dab
substrat
dako
percentag
neutral
calcul
dilut
solut
antibodi
percentag
decreas
fraction
number
foci
compar
viru
without
incub
scfvfc
fusion
protein
irrelev
scfvfc
fusion
protein
use
isotyp
control
doserespons
curv
drawn
nonlinear
regress
analys
variabl
slope
model
frnt
valu
determin
graph
use
graphpad
softwar
examin
bind
activ
antibodi
sftsv
gener
vero
cell
serial
dilut
viral
supernat
sftsv
infect
cell
determin
titer
supernat
mockinfect
cell
coat
onto
microtit
plate
costar
overnight
fifti
five
thousand
pfu
sftsv
use
coat
well
plate
incub
serial
dilut
antibodi
palivizumab
isotyp
control
follow
hrpconjug
antihuman
igg
fc
antibodi
invitrogen
reaction
develop
ad
tmb
substrat
thermo
scientif
termin
ad
sulfur
acid
absorb
measur
nm
amount
viru
coat
micropl
well
indic
top
graph
mean
absorb
standard
deviat
sd
error
bar
shown
antibodi
concentr
absorb
antibodi
bound
sftsvcoat
well
red
palivizumab
bound
sftsvcoat
well
blue
antibodi
bound
mockviru
coat
well
magenta
palivizumab
bound
mockviru
coat
well
purpl
shown
graph
tif
amino
acid
sequenc
gn
glycoprotein
sftsv
isol
deposit
vipr
use
analysi
sequenc
trim
retain
amino
acid
residu
correspond
ectodomain
trim
sequenc
analyz
phylogenet
tree
built
circular
tree
layout
use
neighborjoin
method
jukescantor
genet
distanc
model
name
isol
label
besid
tip
branch
asterisk
tip
branch
indic
isol
test
bind
activ
tif
recombin
sftsv
prepar
sampl
buffer
reduc
agent
invitrogen
sampl
separ
polyacrylamid
gel
invitrogen
electrophoresi
transfer
nitrocellulos
membran
block
wv
skim
milk
trisbuff
salin
ph
membran
incub
ngml
five
sftsv
gn
specif
antibodi
scfvfc
format
gn
bound
antibodi
probe
hrpconjug
antihuman
igg
fc
antibodi
invitrogen
confirm
presenc
protein
hrpconjug
antihuman
ig
kappa
light
chain
antibodi
chemicon
temecula
ca
usa
use
directli
detect
blot
visual
use
chemiluminesc
substrat
thermo
scientif
tif
fig
phylogenet
analysi
sequenc
cover
epitop
amino
acid
sequenc
gn
glycoprotein
sftsv
isol
deposit
vipr
analyz
sequenc
trim
retain
amino
acid
correspond
residu
recogn
trim
sequenc
analyz
phylogenet
tree
built
circular
tree
layout
use
neighborjoin
method
jukescantor
genet
distanc
model
name
isol
written
besid
tip
branch
strain
name
label
red
indic
gn
glycoprotein
indic
strain
predict
interact
tif
